462 related articles for article (PubMed ID: 33459728)
1. State-of-the-art overview on biological treatment for CRSwNP.
Hellings PW; Verhoeven E; Fokkens WJ
Rhinology; 2021 Apr; 59(2):151-163. PubMed ID: 33459728
[TBL] [Abstract][Full Text] [Related]
2. A comparative analysis of endoscopic sinus surgery versus biologics for treatment of chronic rhinosinusitis with nasal polyposis.
Miglani A; Soler ZM; Smith TL; Mace JC; Schlosser RJ
Int Forum Allergy Rhinol; 2023 Feb; 13(2):116-128. PubMed ID: 35980852
[TBL] [Abstract][Full Text] [Related]
3. Efficacy and Safety of Dupilumab Versus Omalizumab in Chronic Rhinosinusitis With Nasal Polyps and Asthma: EVEREST Trial Design.
De Prado Gomez PharmD MSc L; Khan Mbbs Mph AH; Peters Md AT; Bachert Md PhD C; Wagenmann Md M; Heffler Md PhD E; Hopkins BMBCh C; Hellings Md PhD PW; Zhang PhD M; Xing PhD J; Rowe Md P; Jacob-Nara Md Mph DHSc JA
Am J Rhinol Allergy; 2022 Nov; 36(6):788-795. PubMed ID: 35837739
[TBL] [Abstract][Full Text] [Related]
4. Biologic Therapies for Allergic Rhinitis and Nasal Polyposis.
Geng B; Dilley M; Anterasian C
Curr Allergy Asthma Rep; 2021 Jun; 21(6):36. PubMed ID: 34110505
[TBL] [Abstract][Full Text] [Related]
5. Improvement in Smell Using Monoclonal Antibodies Among Patients With Chronic Rhinosinusitis With Nasal Polyps: A Systematic Review.
Barroso B; Valverde-Monge M; Betancor D; Gómez-López A; Villalobos-Vilda C; González-Cano B; Sastre J
J Investig Allergol Clin Immunol; 2023 Dec; 33(6):419-430. PubMed ID: 37669083
[TBL] [Abstract][Full Text] [Related]
6. Which Is the Best Biologic for Nasal Polyps: Dupilumab, Omalizumab, or Mepolizumab? A Network Meta-Analysis.
Wu Q; Zhang Y; Kong W; Wang X; Yuan L; Zheng R; Qiu H; Huang X; Yang Q
Int Arch Allergy Immunol; 2022; 183(3):279-288. PubMed ID: 34607329
[TBL] [Abstract][Full Text] [Related]
7. Efficacy and safety of omalizumab in nasal polyposis: 2 randomized phase 3 trials.
Gevaert P; Omachi TA; Corren J; Mullol J; Han J; Lee SE; Kaufman D; Ligueros-Saylan M; Howard M; Zhu R; Owen R; Wong K; Islam L; Bachert C
J Allergy Clin Immunol; 2020 Sep; 146(3):595-605. PubMed ID: 32524991
[TBL] [Abstract][Full Text] [Related]
8. Mepolizumab improvements in health-related quality of life and disease symptoms in a patient population with very severe chronic rhinosinusitis with nasal polyps: psychometric and efficacy analyses from the SYNAPSE study.
Fokkens W; Trigg A; Lee SE; Chan RH; Diamant Z; Hopkins C; Howarth P; Lund V; Mayer B; Sousa AR; Yancey S; Tabberer M;
J Patient Rep Outcomes; 2023 Jan; 7(1):4. PubMed ID: 36662344
[TBL] [Abstract][Full Text] [Related]
9. Efficacy and safety of dupilumab in patients with severe chronic rhinosinusitis with nasal polyps (LIBERTY NP SINUS-24 and LIBERTY NP SINUS-52): results from two multicentre, randomised, double-blind, placebo-controlled, parallel-group phase 3 trials.
Bachert C; Han JK; Desrosiers M; Hellings PW; Amin N; Lee SE; Mullol J; Greos LS; Bosso JV; Laidlaw TM; Cervin AU; Maspero JF; Hopkins C; Olze H; Canonica GW; Paggiaro P; Cho SH; Fokkens WJ; Fujieda S; Zhang M; Lu X; Fan C; Draikiwicz S; Kamat SA; Khan A; Pirozzi G; Patel N; Graham NMH; Ruddy M; Staudinger H; Weinreich D; Stahl N; Yancopoulos GD; Mannent LP
Lancet; 2019 Nov; 394(10209):1638-1650. PubMed ID: 31543428
[TBL] [Abstract][Full Text] [Related]
10. The Effectiveness of Biological Agents on Chronic Rhinosinusitis with Nasal Polyposis in Patients with Comorbid Asthma: A Multicenter Real-Life Study from Türkiye.
Demir M; Tunakan Dalgic C; Mete Gokmen EN; Savas R; Eroglu S; Ozden G; Orcen C; Pacaci Cetin G; Arslan B; Bilgir F; Bulut G; Akcam NY; Ozgul S; Cerci P; Coskun R; Gode S; Yilmaz I; Sin AZ
Medicina (Kaunas); 2024 Mar; 60(3):. PubMed ID: 38541174
[No Abstract] [Full Text] [Related]
11. Improvement in Olfaction in Patients With CRSwNP and Severe Asthma Taking Anti-IgE and Anti-IL-5 Biologics: A Real-Life Study.
Barroso B; Valverde-Monge M; Alobid I; Olaguibel JM; Rial MJ; Quirce S; Arismendi E; Barranco P; Betancor D; Bobolea I; Cárdaba B; Cruz Carmona MJ; Curto E; Domínguez-Ortega J; González-Barcala FJ; Martínez-Rivera C; Mahíllo-Fernández I; Muñoz X; Picado C; Plaza V; Rodrigo Muñoz JM; Soto-Retes L; Valero A; Del Pozo V; Mullol J; Sastre J
J Investig Allergol Clin Immunol; 2023 Feb; 33(1):37-44. PubMed ID: 35416154
[TBL] [Abstract][Full Text] [Related]
12. Real-life effects of dupilumab in patients with severe type 2 asthma, according to atopic trait and presence of chronic rhinosinusitis with nasal polyps.
Pelaia C; Benfante A; Busceti MT; Caiaffa MF; Campisi R; Carpagnano GE; Crimi N; D'Amato M; Foschino Barbaro MP; Maglio A; Minenna E; Nolasco S; Paglino G; Papia F; Pelaia G; Portacci A; Ricciardi L; Scichilone N; Scioscia G; Triggiani M; Valenti G; Vatrella A; Crimi C
Front Immunol; 2023; 14():1121237. PubMed ID: 37063895
[TBL] [Abstract][Full Text] [Related]
13. Systematic literature review of the epidemiology and clinical burden of chronic rhinosinusitis with nasal polyposis.
Chen S; Zhou A; Emmanuel B; Thomas K; Guiang H
Curr Med Res Opin; 2020 Nov; 36(11):1897-1911. PubMed ID: 32847417
[TBL] [Abstract][Full Text] [Related]
14. Benefits of biologic therapy administered for asthma on co-existent chronic rhinosinusitis: A real-world study.
Bajpai S; Marino MJ; Rank MA; Donaldson AM; O'Brien EK; Lal D
Int Forum Allergy Rhinol; 2021 Aug; 11(8):1152-1161. PubMed ID: 33527730
[TBL] [Abstract][Full Text] [Related]
15. Efficacy and safety of dupilumab in patients with uncontrolled severe chronic rhinosinusitis with nasal polyps and a clinical diagnosis of NSAID-ERD: Results from two randomized placebo-controlled phase 3 trials.
Mullol J; Laidlaw TM; Bachert C; Mannent LP; Canonica GW; Han JK; Maspero JF; Picado C; Daizadeh N; Ortiz B; Li Y; Ruddy M; Laws E; Amin N
Allergy; 2022 Apr; 77(4):1231-1244. PubMed ID: 34459002
[TBL] [Abstract][Full Text] [Related]
16. [Experience of biological therapy in severe forms of chronic rhinosinusitis with nasal polyps in the conditions of regional healthcare].
Larin RA; Mokeeva PP; Grishin AS
Vestn Otorinolaringol; 2023; 88(2):51-58. PubMed ID: 37184555
[TBL] [Abstract][Full Text] [Related]
17. Omalizumab treats chronic rhinosinusitis with nasal polyps and asthma together-a real life study.
Bidder T; Sahota J; Rennie C; Lund VJ; Robinson DS; Kariyawasam HH
Rhinology; 2018 Mar; 56(1):42-45. PubMed ID: 29288573
[TBL] [Abstract][Full Text] [Related]
18. Dupilumab reduces opacification across all sinuses and related symptoms in patients with CRSwNP.
Bachert C; Zinreich SJ; Hellings PW; Mullol J; Hamilos DL; Gevaert P; Naclerio RM; Amin N; Joish VN; Fan C; Zhang D; Staudinger H; Pirozzi G; Graham NMH; Khan A; Mannent LP
Rhinology; 2020 Feb; 58(1):10-17. PubMed ID: 31671432
[TBL] [Abstract][Full Text] [Related]
19. Radiological Versus Clinical 1-Year Outcomes of Dupilumab in Refractory CRSwNP: A Real-Life Study.
Giombi F; Pace GM; Nappi E; Giunta G; Muci G; Pirola F; Ferreli F; Heffler E; Paoletti G; Giannitto C; Mercante G; Francone M; Spriano G; Canonica GW; Malvezzi L
Laryngoscope; 2024 Jun; 134(6):2626-2633. PubMed ID: 38126613
[TBL] [Abstract][Full Text] [Related]
20. Comparison of Different Biologics for Treating Chronic Rhinosinusitis With Nasal Polyps: A Network Analysis.
Cai S; Xu S; Lou H; Zhang L
J Allergy Clin Immunol Pract; 2022 Jul; 10(7):1876-1886.e7. PubMed ID: 35272073
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
